Pure Primary Squamous Cell Carcinomas of the Breast: A Report of Eight Cases

Kaoutar Znati\textsuperscript{a,c}, Sanaa Benni\textsuperscript{a}, Fouad Abbas\textsuperscript{a}, Meriam Chraibi\textsuperscript{a}, Nawal Hammas\textsuperscript{a}, Sanae Chahbouni\textsuperscript{a}, Taoufiq Harmouch\textsuperscript{a}, Laila Chbani\textsuperscript{a}, Hinde Elfatemi\textsuperscript{a}, Yousra Aksbi\textsuperscript{b}, Samia Arifi\textsuperscript{b}, Omar Mesbah\textsuperscript{b}, Afaf Amarti\textsuperscript{a}

Abstract

Pure primary squamous cell carcinoma (PPSCC) of the breast is a rare neoplasm included in World Health Organization Classification of tumors (2003) in metaplastic breast cancer. It accounts for less than 0.1% of all breast carcinomas. We performed a retrospective review of all women diagnosed or treated as PPSCC, from January 2004 to June 2009 to assess clinical presentation, surgical and pathological findings, treatment and outcome. Eight patients were identified. The median age was 48.2 (range: 40 - 57) years. The average tumor size was 7.3 cm, with a range of 3.5 to 18 cm. There were one well differentiated, three moderately differentiated and four poorly differentiated PPSCC. Two cases were stage IIA, two cases stage IIIA and three cases stage IIIB. Primary treatment was mastectomy in six patients and large local excision in one patient. There was lymph node (LN) involvement in one patient. Estrogen and progesterone receptors status and over expression of HER 2 were assessed and none tumors was positive. Cytokeratin 5/6 and/or Cytokeratin 14 were positive in all tumors. All patients were treated by radiotherapy and chemotherapy. Though PPSCC of the breast is a very rare and aggressive disease, in our experience it’s relatively frequent. Strict histologic criteria should be used to diagnose PPSCC, because they have significantly lower axillary lymph node metastasis, lower estrogen and PR positivity, and they are often treatment-refractory. The role of different new chemotherapy regimens needs to be explored.

Keywords: Pure squamous cell carcinoma; Metaplastic carcinoma; Breast; Morphology; Basal-like phenotype; Histogenesis;

Introduction

Pure primary squamous cell carcinoma (PPSCC) of the breast is a rare condition and is considered to arise through metaplastic change of ductal carcinoma cells [1, 2]. In World Health Organization Classification of tumors (2003), it’s included in metaplastic breast cancer [3]. Several pathological criteria are required to establish a firm diagnosis of PPSCC of the breast: (1) a tumor origin that is independent of the overlying skin and nipple or of adnexal elements; (2) more than 90% of the tumor must be squamous; (3) there can be no other invasive neoplastic elements, ductal or mesenchymal, on thorough sampling; and (4) other sites of primary squamous cell carcinoma must be excluded [1].

Clinical and radiological features are not specific and are generally characterized by the absence of expression of hormone receptor and human epidermal growth factor receptor 2 (HER2). Prognosis of this breast cancer is poor and the disease is associated with frequent locoregional and distant metastasis [1, 4]. There is no scientific evidence of the usefulness of adjuvant treatments and more studies are needed [5].

Case Report

Eight cases of PPSCC were diagnosed in the pathology department between January 2004 and June 2009 and were retrospectively reviewed.

Clinical information, including patient age, tumor size, tumor location, specimen type, estrogen receptor (ER), progestosterone receptor (PR), and Her2/neu status was recorded from the pathology reports. The phenotype was designated as “triple negative” if ER and PR expression was recorded as 0% to 5%, Her2/neu expression was 0 or 1+. Expressions of Cytokeratins (Cks), including Ck5/6 and/or Ck14 were assessed to specify basal-like phenotype.

All patients were female, with a median age of 48.2 years (range: 40 - 57 years). The tumor was on the right in three cases, and on the left in five cases. Clinical pre-
presentation was non-specific in two patients and overlying skin was inflammatory in two cases with locally advanced tumors. One patient was initially diagnosed with a breast abscess. There was no evidence of lymphadenopathy on physical examination.

On mammography, all patients had well delineated mass densities with no specific data suggesting this specific diagnosis (Fig. 1).

Total body CT scan, bone scan, laboratory data (blood count, serum electrolytes, liver function tests, creatinine, prothrombin and partial thromboplastin time) and tumor markers were within normal range. No other tumor location was found.

One of the specimens was a large tumorectomy and six were mastectomy specimens. The average tumor size was 7.3 cm, with a range between 3.5 to 18 cm. There were one well differentiated (Fig. 2), three moderately differentiated and 4 poorly differentiated PPSCC (Fig. 3). Intermediate grade ductal carcinoma in situ was found in one case without squamous metaplasia. No other component has been observed. Three patients had neo adjuvant chemotherapy.

The evaluation of therapeutic response based on Sataloff classification was as following: two cases were T-C, N-B and one case was T-C, N-C.

Axillary node dissection results were available for all patients. Eight lymph nodes metastasis were identified in one case, and no positive lymph nodes were identified among the remaining six cases. Two cases were stage IIA, three cases stage IIIA, and two cases stage IIIB.

The tumors had basal-like phenotype. Immunohistochemical staining for estrogen and progesterone receptors and HER-2/neu oncoprotein were negative whereas Ck5/6 and/or Ck14 were positive (Fig. 4). The patients’ Ki-67 proliferation index was high (in 50 to 75% of tumoral cells).

The patients were treated with adjuvant radiotherapy, receiving a total dose of 50 Gy. Three patients, with locally advanced tumors, received neo-adjuvant chemotherapy with cisplatin/docetaxel, whereas four patients received only adjuvant chemotherapy. Three patients were followed from six months to three years with no evidence of recurrence and three patients died. The other two patients were lost to follow.
Discussion

PPSCC is a very rare tumor, with a reported incidence of approximately 0.1% of all ductal carcinomas [6]. In our experience, it accounts for more than 0.5% of all invasive breast cancer and 68% of all metaplastic carcinoma. In PPSCC, all or the majority of the cells, are squamous type with keratinization, and the presence of some glandular features should make us disregard this diagnosis [1-9]. These criteria are critical to distinguish true squamous breast cancers from the common ductal carcinoma not otherwise specified with squamous metaplasia.

The tumors are most often seen in postmenopausal women. Our patients’ median age is 48.2 years. Clinical presentation is not different from that of infiltrating duct carcinoma. Most patients present with a well circumscribed palpable mass, with a median size of 3 - 4 cm. In some reports more than half of these tumors measure over 5cm, with some massive lesions (> 20cm) which may displace the nipple and ulcerate through the skin [1-10]. Like our patients, the tumor occurs very rarely as breast abscess. To the best of our knowledge, only six patients with these tumors, which presented clinically as breast abscess, have been reported previously [11]. There are no findings on mammography specific to this diagnosis, which may explain the more-advanced disease stage at diagnosis [12, 13]. Breast ultrasound has been reported to be more helpful with these tumors appearing as solid hypoechoic masses with complex cystic components [14].

Histogenesis remains controversial. This breast cancer occurs in two clinical situations: (1) complicating benign squamous metaplasia in benign breast conditions without evidence of intraductal carcinoma; and (2) extensive and prominent squamous metaplasia in infiltrating duct carcinoma. The concept of a disease continuum with varying degrees of squamous metaplasia and glandular features was well supported by Stevenson et al [2]. In our report, one tumor included ductal carcinoma in situ without squamous metaplasia which is discordant with that hypothesis.

Macroscopically, the PPSCC present often as large tumors (> 4 cm) at diagnosis. Cystic changes are observed in 50% of the cases [2, 11, 15]. In our experience, the average tumor size was 7.3 cm, with a range of 3.5 to 18 cm.

Microscopically, PPSCC is entirely composed of metaplastic squamous cells that may be keratinizing, non-keratinizing, and less frequently spindle cell and acantholytic types; some show a combination of these patterns. The most bland appearing and well differentiated cells often line cystic spaces. As the tumor cells emanate out to infiltrate the surrounding stroma, they become spindle shaped and loose their squamous features. PPSCC can be graded based mainly on nuclear features and, to a lesser degree, cytoplasmic differentiation. Grading the squamous carcinoma is of uncertain utility [1]. The grading system of usual ductal carcinoma (Nottingham modification of the Bloom-Richardson system) is not applicable to these tumors. Pathologic staging is similar to that used for any mammary carcinoma.

Most of PPSCC are ER, PR, and HER2 (“triple”) negative. The expression of Ck5/6, Ck14 and Ck17, can be used to identify these lesions reliably on tissue sections fixed in formalin and embedded in paraffin [16-18]. Our results support this observation. Indeed all tumors were negative of ER, PR, Her 2 neu or expressed Ck5/6 and/ or Ck14.

These tumors are also associated with a significantly lower rate of axillary lymph node metastasis compared to usual ductal adenocarcinoma of the breast [1, 5]. Metastases to axillary nodes in all patients with PPSCC have been reported to range from 10% to 30% [1, 4, 5]. This is lower than the reported rates of 40-60% in usual ductal adenocarcinomas. This is unlike cutaneous squamous cell carcinomas that tend to metastasize to regional lymph nodes. In fact, many authors report that PPSCC is likely to skip regional nodes and present with distant metastasis, with rates reported in the range of 30-33% [1, 4, 5].

The prognosis is still a subject of controversy; some reports suggest that it is aggressive, with an outcome comparable to poorly differentiated ductal carcinoma of the breast [1, 5, 7, 9]. Large tumor size and positive lymph node status were found to be the principle features of poor prognosis [1].

Rapidly progressive PPSCC is reported to be associated with a prominent spindle cell component or the presence of necrosis and acantholytic features. Yamagachi et al indicate that the presence of high-grade spindle cells in PPSCC was at least one important prognostic factor [19]. The 5-year disease-free survival for this tumor has been reported to be 63% [20] and 52% [21].

Because of its rarity the most appropriate therapeutic regimen for PPSCC of the breast is still unclear. PPSCC is usually a hormone receptor-negative tumor [3]. This means that hormone based therapy may not be effective in these tumors. HER2/neu is also usually not over-expressed or amplified in this disease [12]. A little review suggests that PPSCC is not sensitive to chemotherapeutic agents commonly used for ductal carcinoma [6, 22]. In our experience, three patients received neo adjuvant chemotherapy and had a low therapeutic response on histologic examination. The high frequency of EGFR positivity is interesting. The use of anti-EGFR, combined with synergic cytotoxic agents such as Platin or Taxanes, should be investigated in clinical trials which should be ideally multicentric, given the low frequency of this tumor [23]. The role of radiation has been reported as unclear in many studies. Indeed locoregional relapse occurred frequently also in irradiated field.

In conclusion, PPSCC of the breast is a very rare and aggressive disease. In our experience it’s relatively frequent. Strict histologic criteria should be used to diagnose PPSCC, because they have significantly lower axillary lymph node
metastasis, lower estrogen and PR positivity, and are often treatment-refractory. The role of different new chemotherapy regimens needs to be explored and biologic studies are needed to determine the tumor chemoresistance mechanisms and the potential use of other treatment targets that improve patients’ survival.

**Conflict of Interest**

There is no conflict of interest and no study sponsors. The authors have obtained the patients’ written informed consent for print and electronic publication of the case report.

**References**

3. World Health Organization classification of Tumours. In: Tavassoli FA, Devilee P, editors. Tumours of. Pathol -
5. World Health Organization classification of Tumours. In: Tavassoli FA, Devilee P, editors. Tumours of Pathol -